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Abstract: Brain endothelial cells play an essential role as structural and functional components 
of the blood–brain barrier (BBB). Increased BBB breakdown and brain injury are associated with 
neuroinflammation and are thought to trigger mechanisms involving matrix metalloproteinase 
upregulation. Emerging evidence also indicates that cyclooxygenase (COX) inhibition limits 
BBB disruption, but the mechanisms linking metalloproteinase to COX remain unknown. In this 
study, we sought to investigate the nuclear factor-kappa B (NF-κB) signaling pathway, a common 
pathway in both the regulation of matrix metalloproteinase-9 (MMP-9) and COX-2 expression, 
and the inhibitory properties of several chemopreventive flavonoids. Human brain microvascular 
endothelial cells were treated with a combination of phorbol 12-myristate 13-acetate (PMA), 
a carcinogen documented to increase MMP-9 and COX-2 through NF-κB, and several naturally 
occurring flavonoids. Among the molecules tested, we found that fisetin, apigenin, and luteolin 
specifically and dose-dependently antagonized PMA-induced COX-2 and MMP-9 gene and 
protein expressions as assessed by qRT-PCR, immunoblotting, and zymography respectively. 
We further demonstrate that flavonoids impact on IκK-mediated phosphorylation activity as 
demonstrated by the inhibition of PMA-induced IκB phosphorylation levels. Our results sug-
gest that BBB disruption during neuroinflammation could be pharmacologically reduced by a 
specific class of flavonoids acting as NF-κB signal transduction inhibitors.
Keywords: blood–brain barrier, flavonoids, neuroinflammation, NF-κB signal transduction 
inhibitors
Introduction
Tumor-associated angiogenesis, a fundamental process in tumor growth and metastasis, 
consists of recruiting endothelial cells (EC) toward an angiogenic stimulus.1 The cells 
subsequently proliferate and differentiate to form endothelial tubes and capillary-like 
structures in order to deliver nutrients and oxygen to the tumor and to remove the 
products of its metabolism. In recent years, several pathways have, in addition to 
stimulation of tumor angiogenesis, been suggested to contribute to the cell metabolic 
adaptations required for carcinogenesis, which include decreased tumoral   apoptosis, 
increased invasion and metastasis, immune suppression, and tumor-associated 
inflammation.2,3 An interesting link between overexpression of the proinflammatory 
marker cyclooxygenase (COX)-2 and tumor angiogenesis was recently described as 
one such metabolic adaptive phenotype.4–6 This is supported by the fact that in a normal 
cerebral cortex, COX-2 is only present in neurons but absent from vascular EC.7,8 
It is however still unknown whether the EC-associated COX-2 correlates with high 
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metabolic adaptation of EC in response to procarcinogenic 
stimuli. It is tempting to suggest that specific inhibition of 
metabolic pathways may offer a novel therapeutic approach 
that would simultaneously inhibit tumor-induced angiogen-
esis and inflammatory phenotypes.9,10
While human brain microvascular endothelial cells 
(HBMEC) play an essential role as structural and functional 
components of the blood–brain barrier (BBB), its disruption by 
the brain tumor-secreted matrix metalloproteinase-9 (MMP-9) is 
believed to favor tumor invasion.11,12 Recent studies delineated a 
unique brain endothelial phenotype in which MMP-9 secretion 
by HBMEC was increased upon treatment with the tumor-
promoting agent phorbol 12-myristate 13-acetate (PMA).13,14 
Inhibition of MMP-9 secretion was demonstrated to reduce 
both in vitro invasion and angiogenesis in human microvascular 
EC.15 Among strategies developed to inhibit extracellular matrix 
(ECM) degradation and inflammation processes, the design, 
synthesis, and evaluation of flavonoid derivatives has recently 
emerged as a potent strategy to target neurodegenerative 
disorders including different forms of dementia, as well as 
Alzheimer’s disease.16 In fact, a large number of mechanisms 
of action have been attributed to flavonoids commonly found 
in fruits, vegetables, wine, or tea as they can act as potent 
antioxidants and free radical scavengers.17,18 The rationale 
underlying the selection of flavones and related compounds 
was herein dictated by the known activity of apigenin against 
several forms of cancer, including leukemia, due in part to its 
action through JAK/STAT and PI3K/PKB signaling pathways.19 
Thus, apigenin, luteolin, and fisetin were considered potential 
good candidates possessing polyphenolic functions capable of 
counteracting oxidative mechanisms. Indeed, the three com-
pounds are lacking hydrophilic sugar or sugar-like moieties, and 
consequently, they are more hydrophobic and bear drug-like 
properties that characterize leads in drug discovery. Quercitrin 
was also chosen because it has a very similar structure to that 
of fisetin and yet exposes a rhamnoside residue which renders 
it more closely related to the other family of tested compounds 
(chlorogenic acid, arbutin, salicin, phlorizin, and coniferin), 
hence filling the gap for our QSAR profiles. These phenolic 
glycosides, while possessing some structurally related features, 
do not have the key flavone backbone.
Among the signaling pathways, NF-κB signaling 
is the one that enables the control of both MMP-9 and 
COX-2 inflammation marker expression.20,21 This current 
study therefore focuses on flavonoids as potential signal 
transduction inhibitors of carcinogen-mediated induction of 
the NF-κB pathway in a brain EC model. Eight flavonoids 
were evaluated: flavonol, fisetin; flavones, apigenin and 
luteolin; flavonol-glycoside, quercitrin; chlorogenic acid; 
and a few phenolic glucosides – arbutin, salicin, phlorizin, 
and coniferin. The aim of the study was to relate the struc-
tural differences of the flavonoids to their potency to inhibit 
PMA-induced MMP-9 and COX-2 expression in HBMEC.
Materials and methods
reagents
Sodium dodecylsulfate (SDS) and bovine serum albumin 
were purchased from Sigma (Oakville, ON). Electrophoresis 
reagents were purchased from Bio-Rad (Mississauga, ON). 
The enhanced chemiluminescence reagents were from Perkin 
Elmer (Waltham, MA). Micro bicinchoninic acid protein assay 
reagents were from Pierce (Rockford, IL). The polyclonal 
antibodies against IκB and phospho-IκB were purchased 
from Cell Signaling (Danvers, MA). The monoclonal anti-
body against GAPDH was from Advanced Immunochemical, 
Inc (Long Beach, CA). Horseradish peroxidase-conjugated 
donkey anti-rabbit and anti-mouse IgG secondary antibod-
ies were from Jackson ImmunoResearch Laboratories (West 
Grove, PA). All other reagents were from Sigma-Aldrich 
Canada. Eight flavonoids were evaluated: flavonol, fisetin 
(2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one); 
flavones, apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)-
4H-1-benzopyran-4-one)  and  luteolin  (2-(3,4-
dihydroxyphenyl)-5,7-dihydroxy-4-chromenone); the 
flavonol-glycoside quercitrin (2-(3,4-dihydroxyphenyl)-5,7-
dihydroxy-3-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-
2-tetrahydro-pyranyl]oxy}-4-chromenone); chlorogenic 
acid ((1S,3R,4R,5R)-3-{[(2Z)-3-(3,4-dihydroxyphenyl)
prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexanecarbox-
ylic acid); as well as a few phenolic glucosides – arbutin 
((2R,3S,4S,5R,6S)-2-hydroxymethyl-6-(4-hydroxyphenoxy)
oxane-3,4,5-triol),   salicin ((2R,3S,4S,5R,6S)-2-(hydroxymethyl)-
6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol), 
phlorizin (1-{2,4-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-
phenyl}-3-(4-hydroxyphenyl)propan-1-one), and coniferin 
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-{4-[(E)-3-hydroxy-
prop-1-enyl]-2-methoxyphenoxy}oxane-3,4,5-triol. The 
phenolic flavonoid derivatives were either purchased from 
Sigma-Aldrich (St Louis, MO) or donated from the personal 
collection of Prof Ragai K Ibrahim from the University of 
Concordia (Montreal, QC).
cell culture
Human brain microvascular endothelial cells (HBMEC) 
were characterized and generously provided by Dr Kwang Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Sik Kim of the Johns Hopkins University School of 
  Medicine   (Baltimore, MD). These cells were positive for 
factor VIII-Rag, carbonic anhydrase IV , and Ulex europaeus 
Agglutinin I; they took up fluorescently labeled, acetylated 
low-density lipoprotein and expressed gamma glutamyl trans-
peptidase, demonstrating their brain EC-specific phenotype.18 
HBMEC were immortalized by transfection with simian 
virus 40 large T antigen, and maintained their morphologi-
cal and functional characteristics for at least 30 passages.22 
HBMEC were maintained in RPMI 1640 (Gibco, Burlington, 
ON) supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum (iFBS) (HyClone Laboratories, Logan, UT), 
10% (v/v) NuSerum (BD Bioscience, Mountain View, CA), 
modified Eagle’s medium nonessential amino acids (1%) 
and vitamins (1%) (Gibco), sodium pyruvate (1 mM), and 
EC growth supplement (30 µg/mL). Culture flasks were 
coated with 0.2% type-I collagen to support the growth of 
HBMEC monolayers. Cells were cultured at 37°C under a 
humidified atmosphere containing 5% CO2. All experiments 
were performed using passages 3 to 28.
gelatin zymography
Gelatin zymography was used to assess the extent of 
proMMP-9 activity as previously described.23 Briefly, an 
aliquot (20 µL) of the culture medium was subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) in a gel containing 0.1 mg/mL gelatin. The gels 
were then incubated in 2.5% Triton X-100 and rinsed in 
nanopure distilled H2O. Gels were further incubated at 
37°C for 20 hours in 20 mM NaCl, 5 mM CaCl2, 0.02% 
Brij-35, 50 mM Tris-HCl buffer, pH 7.6, then stained with 
0.1% Coomassie Brilliant Blue R-250, and destained in 10% 
acetic acid, 30% methanol in H2O. Gelatinolytic activity was 
detected as unstained bands on a blue background.
immunoblotting procedures
Proteins from control and treated cells were separated by 
SDS-PAGE. After electrophoresis, proteins were elec-
trotransferred to polyvinylidene difluoride membranes 
which were then blocked for 1 hour at room temperature 
with 5% nonfat dry milk in Tris-buffered saline (150 mM 
NaCl, 20 mM Tris-HCl, pH 7.5) containing 0.3% Tween-20 
(TBST). Membranes were further washed in TBST and incu-
bated with the primary antibodies (1/1,000 dilution) in TBST 
containing 3% bovine serum albumin and 0.1% sodium azide, 
followed by a 1 hour incubation with horseradish peroxidase-
conjugated anti-rabbit or anti-mouse IgG (1/2,500 dilution) 
in TBST containing 5% nonfat dry milk. Immunoreactive 
material was visualized by enhanced chemiluminescence 
(Amersham Biosciences, Baie d’Urfée, QC).
Total rnA isolation, cDnA synthesis,  
and real-time quantitative rT-Pcr
Total RNA was extracted from cell monolayers using TriZol 
reagent (Life Technologies, Gaithersburg, MD). For cDNA 
synthesis, 2 µg of total RNA were reverse-transcribed using 
a high capacity cDNA reverse transcription kit (Applied 
Biosystems, Foster City, CA). cDNA was stored at −80°C 
prior to PCR. Gene expression was quantified by real-time 
quantitative PCR using iQ SYBR Green Supermix (Bio-Rad, 
Hercules, CA). DNA amplification was carried out using an 
Icycler iQ5 (Bio-Rad), and product detection was performed 
by measuring binding of the fluorescent dye SYBR Green I 
to double-stranded DNA. The QuantiTect primer sets were 
provided by Qiagen (Valencia, CA): MMP-9 (QT00040040), 
COX-2 (QT00040586), β-Actin (QT01136772). GAPDH 
primer sets were synthesized by Biocorp (Dollard-des-
Ormeaux, QC) with the following sequences: forward 
CCATCACCATCTTCCAGGAG and reverse CCTGCT-
TCACCACCTTCTTG. The relative quantities of target gene 
mRNA compared against two internal controls, GAPDH and 
β-Actin mRNA, were measured by following a ∆CT method 
employing an amplification plot (fluorescence signal vs cycle 
number). The difference (∆CT) between the mean values in 
the triplicate samples of target gene and those of GAPDH 
and β-actin mRNAs were calculated by iQ5 Optical System 
Software (v 2.0; Bio-Rad), and the relative quantified value 
(RQV) was expressed as 2−∆CT.
endothelial cell morphogenesis assay
Tubulogenesis was assessed using Matrigel aliquots of 50 µL, 
plated into individual wells of 96-well tissue culture plates 
(Costar, Amherst, MA) and allowed to polymerize at 37°C 
for 30 minutes. After brief trypsinization, HBMEC were 
washed and resuspended at a concentration of 106 cells/mL 
in serum-free medium. Twenty-five µL of cell suspension 
(25,000 cells/well) and 75 µL of medium with serum were 
added into each culture well. Cells were allowed to form cap-
illary-like tubes at 37°C in 5% CO2/95% air for 20 hours in 
the presence or absence of 30 µM of the tested molecules. The 
formation of capillary-like structures was examined micro-
scopically and images (10×) were recorded using a Retiga 
1300 camera (QImaging, Surrey, BC) and a Nikon Eclipse 
TE2000-U microscope (Tokyo, Japan). The extent to which 
capillary-like structures formed in the gel was quantified by 
analysis of digitized images to determine the thread length Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of the capillary-like network, using a   commercially available 
image analysis program (Northern Eclipse,   Mississauga, 
ON) as described and validated previously.24,25 For each 
experiment, four randomly chosen areas were quantified by 
counting the number of tubes formed. Tubulogenesis data 
are expressed as a mean value derived from at least three 
independent experiments.
statistical data analysis
Data are representative of three or more independent experi-
ments. Statistical significance was assessed using Student’s 
unpaired t-test. Probability values of less than 0.05 were 
considered significant and an asterisk identifies such signifi-
cance in the figures.
Results
Fisetin, apigenin, and luteolin inhibit hBMec 
in vitro capillary-like structure formation
The effects of chlorogenic acid and of eight structurally related 
phenolic derivatives (Figure 1), all natural molecules present in 
plants, were tested on HBMEC. Matrigel induced tubulogenesis 
assay was used to assess the effect of flavonoids and phenolic 
derivatives on capillary-like structure formation in HBMEC. 
As described in the Methods section, cells were seeded on 
top of Matrigel and left to adhere. Several tested compounds 
were then added and capillary formation left to proceed for 
18 hours. We found that, in vehicle-treated cells as well as 
in chlorogenic acid-, arbutin-, salicin-, phlorizin-, coniferin-, 
and quercitrin-treated cells, capillary-like formation was well-
defined (Figure 2A) in comparison to cells exposed to 30 µM of 
the nonglycosidic flavonoids apigenin, luteolin, or fisetin, which 
had their structures significantly disrupted (Figure 2B).
Flavonoids inhibition of carcinogen-induced 
MMP-9 gene expression and protein 
secretion
Among the secreted enzymes involved in ECM degradation, 
matrix metalloproteinases (MMP) are well-documented 
as being involved in cell migration and tubulogenesis.13,26 
MMP-9, an enzyme involved in the degradation of the ECM, 
is secreted by a variety of cells and its presence was shown to 
be increased upon carcinogen promoting agents such as the 
phorbol ester PMA.27–29 HBMEC were treated for 18 hours 
with the above mentioned flavonoids in serum-free medium. 
Gelatin zymography (Figure 3A) was then used to measure 
MMP-9 levels, which were significantly increased upon PMA 
treatment in comparison to vehicle-treated cells (Figure 3B). 
Addition of the nonglycosidic flavonoids fisetin, apigenin, 
or luteolin to PMA-treated cells resulted in inhibition of 
MMP-9 activity (Figure 3B). It was found that PMA also 
increased MMP-9 gene expression while the presence of 
fisetin, apigenin, or luteolin inhibited this increase, suggesting 
transcriptional regulation of the MMP-9 gene (Figure 3C). 
The anti-MMP-9 effects of fisetin, apigenin, and luteolin were 
also found to be dose-dependent as assessed by zymography 
(Figure 4A), with a Ki of 1.6 µM, 2.2 µM, and 8.3 µM respec-
tively for fisetin, luteolin, and apigenin (Figure 4B).
Flavonoids inhibition of carcinogen-induced 
cOX-2 gene and protein expression
Various molecular mechanisms mediate inflammatory pro-
cesses and angiogenesis, one of which is reflected by increased 
expression of the inflammatory biomarker COX-2.30 In order 
to investigate the effect of flavonoids on HBMEC-associated 
inflammation, we tested the effects of the flavonoids on 
PMA-induced cell signaling in HBMEC by Western blotting. 
Cells were therefore treated with 1 µM of PMA in the 
presence of 30 µM of the flavonoid for 18 hours and COX-2 
expression was evaluated in cell lysates by   Western Blotting 
(Figure 5A). We found that the   nonglycosidic derivatives 
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fisetin, apigenin, and luteolin significantly inhibited COX-2 
protein (Figure 5B) and gene (Figure 5C) expression in the 
presence of PMA, whereas PMA-induced COX-2 expression 
was not affected by the other molecules. Further experiments 
were performed by treating HBMEC with various concentra-
tions of fisetin, apigenin, or luteolin in the presence of PMA 
for 18 hours (Figure 6A). These molecules were found to 
inhibit the COX-2 protein expression in a dose-dependent 
manner (Figure 6B).
carcinogen-induced iκB phosphorylation 
is inhibited by fisetin, luteolin, and apigenin
Among MMP-9 expression regulators, the nuclear factor-
kappaB (NF-κB) signaling pathway has been demonstrated 
to link cancer to inflammatory diseases.31 We therefore 
assessed whether this signaling was activated upon PMA 
treatment and whether it was reflected in IkappaB (IκB) 
degradation. HBMEC were serum-starved then treated with 
1 µM PMA up to 25 minutes, lysates were isolated and IκB 
phosphorylation was assessed through Western Blotting 
(Figure 7A, upper panel). PMA signaling led to the phos-
phorylation of IκB at 15 minutes, followed by a decrease 
in IκB expression   (Figure 7A, lower panel).32 Inhibition of 
PMA-mediated phosphorylation of IκB was next assessed 
in order to demonstrate whether this mechanism contributes 
to the anti-MMP-9 and anti-COX-2 inhibitory activities of 
the best three flavonoids identified above. Preincubation 
with fisetin, luteolin, or apigenin followed by a 15 minute 
PMA treatment led to IκB phosphorylation and to a con-
comitant dose-dependent decrease in IκB for apigenin only 
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(Figure 7B). Inhibition of IκB phosphorylation by fisetin 
and luteolin led to   reappearance of IκB. The ratios of phos-
phorylated IκB over total IκB expression were quantified by 
scanning densitometry and represented (Figure 7C).
Discussion
The adaptive mechanisms responsible for EC survival under 
procarcinogenic conditions remain poorly   documented. 
EC are believed to be metabolically robust and to adapt 
to procarcinogenic paracrine stimulation and conditions 
such as those encountered within the hypoxic tumor 
microenvironment.33,34 Although increasing interest has 
been manifested towards cancer therapies that target cell 
metabolism, very few studies have specifically assessed 
the combined impact of targeting the EC angiogenic and 
inflammatory phenotype. In our study, we induced in vitro 
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procarcinogenic stimulation of brain microvascular endothe-
lium using PMA in combination with naturally occurring 
flavonoids and phenolic glycosides in order to assess their 
anti-angiogenic and anti-inflammatory properties. In vitro 
tubulogenesis, PMA-induced MMP-9 secretion, and expres-
sion of COX-2 were therefore assessed in order to provide a 
metabolic and adaptive link between endothelial inflamma-
tion and angiogenesis.
Our study highlights the combined anti-angiogenic 
and anti-inflammatory effects of nonglycosidic flavonoids 
against carcinogen-stimulated HBMEC, as demonstrated 
by decreased MMP-9 and COX-2 expression biomarkers. 
We showed that fisetin, apigenin, and luteolin, upon pro-
carcinogenic stimulation with PMA, efficiently inhibited 
both MMP-9 secretion and COX-2 expression in HBMEC, 
an inhibitory effect that we believe to be mediated through 
the common NF-κB signaling pathway that regulates both 
biomarkers’ gene and protein expression. Our findings sup-
port those obtained in several other cell models. In fact, 
fisetin’s anti-inflammatory effects were found to suppress 
lipopolysaccharide-induced NF-κB activation in macrophage 
and dendritic cell maturation,35 and in tumor necrosis factor-
induced NF-κB activation in human lung adenocarcinoma 
cells.36 Since fisetin and quercitrin have analogous aglyconic 
structures, the lack of activity of the latter points toward the 
aglycons as the pharmacophoric entity. This is somewhat 
clearly illustrated in comparison with the phenolic glyco-
sides, which have phenols in common but are missing the 
flavonoid skeleton. As for apigenin, several studies reported 
suppression of PMA-induced tumor cell invasion,37 of PMA-
induced COX-2 transcriptional activity,38 and inhibition of 
inflammatory mediators release in human mast cell lines.39 
Finally, luteolin was found to suppress phorbol ester TPA 
(a mimic of diacylglycerol and PKC activator)-induced 
MMP-9 activation in a glioblastoma cell line model.40 
Altogether, our findings not only support the potential anti-
inflammatory properties of those three molecules reported 
in tumoral and immune compartments, they now further 
highlight important anti-angiogenic effects on the vascular 
compartment as reflected through the inhibition of in vitro 
tubulogenesis and carcinogen-induced MMP-9.
To date, only few reports documented an association 
between COX-2 expression and ECM degradation conse-
quent to procarcinogenic stimulation. Among the numerous 
signaling pathways triggered by procarcinogenic culture 
conditions, NF-κB is at the crossroads of both MMP-9 and 
COX-2 regulation by PMA, but the intracellular players still 
remain undefined, at least within the anti-angiogenic effects 
we report herein. Among the intracellular events that could 
link PMA-induced signaling to COX-2 induction, NF-κB 
can contribute to regulate the expression of COX-2 through 
endoplasmic reticulum (ER) stress and, in part, through induc-
tion of the ER chaperone GRP78/BiP, which is expressed at 
high levels in a variety of tumors and which confers drug 
resistance to both proliferating and dormant cancer cells.16 
Importantly, it was recently demonstrated that partial reduc-
tion of GRP78 substantially reduced tumor microvessel 
  density.17 On the other hand, moderate activity of the ER stress 
response system exerts an anti-apoptotic function and supports 
tumor cell survival and chemoresistance, whereas more severe 
aggravation may exceed the protective capacity of this system 
and turn on its pro-apoptotic module.41 In a recent study, we 
further demonstrated in vitro through the combination of two 
pharmacologic approaches that increased COX-2 expression 
only occurs within those EC which possess low intracellular 
ATP levels and which are cultured under procarcinogenic 
conditions.42 Noteworthy, luteolin was shown to change ATP 
levels and trigger ER stress-induced cell death.43
Several flavonoids have also been reported to interfere 
with the oxidative damage activity of inducible nitric oxide 
synthase activity, and to play a nitric oxide scavenging role 
in the therapeutic effects of flavonoids.44 Nitric oxide is 
produced by several different types of cells, including EC 
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of fisetin, luteolin, and apigenin in combination with vehicle or 1 µM PMA for 
18 hours. A) conditioned media were then harvested and gelatin zymography was 
performed in order to detect PMA-induced proMMP-9 and hydrolytic activity as 
described in the Materials and Methods section. B) scanning densitometry was used 
to quantify the extent of proMMP-9 gelatinolytic activity in treated cells. Data shown 
is representative of two independent experiments.
Abbreviations:  hBMec,  human  brain  microvascular  endothelial  cells;  MMP-9, 
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Figure 5 Flavonoids inhibition of carcinogen-induced cOX-2 gene and protein expression. A) HBMEC were serum-starved in the presence of various flavonoids (30 µM) 
in combination with vehicle or 1 µM PMA for 18 hours. Lysates were isolated, electrophoresed via sDs-PAge, and immunodetection of cOX-2 and gAPDh performed as 
described in the Materials and Methods section. B) scanning densitometry of cOX-2 expression was only performed in PMA-treated cells since no cOX-2 was detectable 
in vehicle-treated cells. Densitometric data of a representative blot is shown. C) Total rnA isolation, rT-Pcr, and qPcr were performed as described in the Materials and 
Methods section to assess cOX-2 gene expression in the above-described conditions. Data are representative of three independent qPcr experiments.
Note: *Significant at P , 0.05.
Abbreviations: cOX-2, cyclooxygenase-2; hBMec, human brain microvascular endothelial cells; PMA, phorbol 12-myristate 13-acetate; qrT-Pcr, quantitative reverse 
transcription-polymerase chain reaction; sDs-PAge, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
and macrophages. When flavonoids are used as antioxidants, 
free radicals are scavenged and therefore can no longer react 
with nitric oxide, resulting in less damage. Selected phenolic 
compounds were also shown to inhibit both the COX and 
5-lipoxygenase pathways.45 Moreover, the anti-inflammatory 
ability of flavonoids to inhibit eicosanoid biosynthesis, 
such as prostaglandins which are the end products of the 
COX and lipoxygenase pathways, has also been reported.46 
The exact mechanism by which flavonoids inhibit these 
enzymes is not clear.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Figure 6 Dose-dependent inhibition of COX-2 expression by fisetin, luteolin, and apigenin. HBMEC were serum-starved in the presence of various concentrations of fisetin, 
luteolin, and apigenin in combination with vehicle or 1 µM PMA for 18 hours. A) Lysates were isolated, electrophoresed via sDs-PAge, and immunodetection of cOX-2 
and gAPDh performed as described in the Materials and Methods section. B) scanning densitometry of cOX-2 expression was only performed in PMA-treated cells since 
no cOX-2 was detectable in vehicle-treated cells. Densitometric data of a representative blot out of three is shown.
Abbreviations: cOX-2, cyclooxygenase-2; hBMec, human brain microvascular endothelial cells; PMA, phorbol 12-myristate 13-acetate; sDs-PAge, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis.
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Figure 7 carcinogen-induced iκB phosphorylation is inhibited by fisetin, luteolin, and apigenin. A) hBMec were serum-starved for 30 minutes then treated with 1 µM 
PMA for the indicated time. Lysates were isolated, electrophoresed via sDs-PAge and immunodetection of phosphorylated iκB (P-iκB) and iκB proteins was performed as 
described in the Materials and Methods section. B) hBMec were serum-starved for 30 minutes in the presence of either vehicle or 30 µM fisetin, luteolin, and apigenin. Cells 
were then incubated for 15 minutes with 1 µM PMA. Lysates were isolated, electrophoresed via sDs-PAge and immunodetection of phosphorylated iκB (P-iκB), iκB, and of 
gAPDh proteins was performed as described in the Materials and Methods section. C) Quantification was performed by scanning densitometry of the autoradiograms. Data 
were expressed as the percent of basal P-iκB/iκB ratios in vehicle pretreated cells. Densitometric data of a representative blot out of three is shown.
Abbreviations: hBMec, human brain microvascular endothelial cells; PMA, phorbol 12-myristate 13-acetate; sDs-PAge, sodium dodecyl sulfate polyacrylamide gel 
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In summary, the present study has allowed the 
  identification and molecular characterization of three 
specific flavonoids to act as inhibitors of EC-mediated 
tubulogenesis, and as signal transduction inhibitors against 
carcinogen-mediated induction of COX-2 and MMP-9, while 
phenolic glycosides were shown to be inactive including 
quercitrin, a closely related rhamnosylated analog of the 
above flavonoids. Since fisetin and quercitrin have analogous 
aglyconic structures, the lack of activity of the latter points 
toward the aglycons as the pharmacophoric entity. This is 
somewhat clearly illustrated in comparison with the phenolic 
glycosides, which have phenols in common but are missing 
the flavonoid skeleton. Moreover, we provide evidence that 
the NF-κB pathway may be inhibited through the targeting 
of IκK phosphorylation capacity that ultimately may reduce 
both the acquisition of a proinflammatory phenotype, as 
reflected by decreased COX-2 expression, and the acquisi-
tion of pro-angiogenic phenotype, as reflected by a decrease 
in MMP-9. Our results therefore suggest that BBB disrup-
tion during neuroinflammation could be pharmacologically 
reduced by a specific class of flavonoids acting as NF-κB 
signal transduction inhibitors.
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